Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | NQO2 | P16083 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MIF | P14174 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31470226 | 1.00 | CYP3A4 (0.45) | CYP3A4TSHRRECQLNQO2LMNA | |
| SCHEMBL2770751 | 0.87 | SMN1; SMN2 (0.47) | NQO2MIFCA12CA1CA9 | |
| SCHEMBL29958958 | 0.87 | SMN1; SMN2 (0.47) | NQO2MIFCA12CA1CA9 | |
| SCHEMBL29618957 | 0.87 | HPGD (0.47) | NQO2LMNAMIFCYP1A2POLB | |
| SCHEMBL24362149 | 0.87 | HPGD (0.47) | NQO2LMNAMIFCYP1A2POLB | |
| SCHEMBL4568018 | 0.87 | NLRP3 (0.55) | CYP3A4TSHRLMNANPSR1CYP1A2 | |
| SCHEMBL20865561 | 0.84 | ALDH1A1 (0.56) | CYP3A4LMNANPSR1CA12CA1 | |
| SCHEMBL13636114 | 0.83 | CYP17A1 (0.44) | NQO2LMNANPSR1MIFPOLB | |
| SCHEMBL20057682 | 0.83 | AAK1 (0.47) | NQO2LMNAMIFPOLBRXFP1 | |
| SCHEMBL18511360 | 0.83 | LMNA (0.43) | CYP3A4TSHRLMNANPSR1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559504-B2 | Benzotriazole derivative | UBE CORPORATION (JP) | 2026-02-24 | — | — | US | disclosed |
| EP-3978073-B1 | 1H-BENZO[D][1,2,3]TRIAZOLE DERIVATIVES AS KEAP1 INHIBITORS FOR THE TREATMENT OF RENAL DISEASES | UBE CORP (JP) | 2025-10-15 | — | — | EP | disclosed |
| US-20220259223-A1 | BENZOTRIAZOLE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2022-08-18 | — | — | US | disclosed |
| US-20220259223-A1 | BENZOTRIAZOLE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2022-08-18 | — | — | US | disclosed |
| EP-3978073-A1 | BENZOTRIAZOLE DERIVATIVE | Ube Industries, Ltd. (JP) | 2022-04-06 | — | — | EP | disclosed |
| US-8304557-B2 | Fused heterocycle derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8304557-B2 | Fused heterocycle derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-06 | — | — | US | disclosed |
| US-20090163488-A1 | FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-25 | — | — | US | disclosed |
| US-20090163488-A1 | FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-25 | — | — | US | disclosed |
| WO-2008150015-A1 | HETEROBICYCLIC COMPOUNDS AS KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559504-B2 | Benzotriazole derivative | KEAP1, NFE2L2, NCOR1 | CYP3A4 259/4885TSHR 2245/4885RECQL 3886/4885 |
| US-20220259223-A1 | BENZOTRIAZOLE DERIVATIVE | KEAP1, NFE2L2, BACH1 | CYP3A4 744/4885TSHR 4053/4885RECQL 3397/4885 |
| US-20090163488-A1 | FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF | NOX3, NOX5, ZYX | CYP3A4 638/4885TSHR 716/4885RECQL 4238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.